Hydrophobic acrylate-acrylamide copolymers for ophthalmic devices

US9864102B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9864102-B2
Application numberUS-201514967780-A
CountryUS
Kind codeB2
Filing dateDec 14, 2015
Priority dateDec 16, 2014
Publication dateJan 9, 2018
Grant dateJan 9, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Acrylate-acrylamide copolymers are disclosed. They are rigid and glassy in dry state at room temperature (from about 23° C. to about 28° C.), but are soft and very deformable and have a high refractive index, a high glistening resistance and a low aging-related surface light scattering in fully hydrated state. They are particularly suitable for making wet-packed intraocular lenses (IOLs) which can be delivered through sub 2.0 mm incisions.

First claim

Opening claim text (preview).

We claim: 1. A polymeric ophthalmic device material, which is polymerization product of a polymerizable composition comprising (a) from about 20% to about 35% by weight of N,N dimethylacrylamide relative to the total amount of all polymerizable components, (b) from about 60% to about 70% by weight of one or more aryl acrylic monomers of formula (I) relative to the total amount of all polymerizable components  wherein A 1 is H or CH 3 ; B 1 is (CH 2 ) m1 or [O(CH 2 ) 2 ] z1 in which m1 is 2-6 and z1 is 1-10; Y 1 is a direct bond, O, S, or NR′ in which R′ is H, CH 3 , C n′ H 2n′+1 in which n′=1-10, iso-OC 3 H 7 , C 6 H 5 , or CH 2 C 6 H 5 ; W1 is 0-6, provided that m1+w1≦8; and D 1 is H, Cl, Br, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 6 H 5 , or CH 2 C 6 H 5 , (c) a polymerizable crosslinking agent, wherein the listed components and any additional polymerizable components add up to 100% by weight, wherein the sum of the amounts of components (a) and (b) is at least 90% by weight, wherein the ophthalmic device material in a dried state has a glass transition temperature of from about 28° C. to about 40° C., wherein the ophthalmic device material in a fully-hydrated state has: a glass transition temperature of less than 20° C., a refractive index of greater than 1.50 measured at 589 nm and at room temperature (23±3° C.), an equilibrium water content of from about 1.5% to about 3.9% by weight at a temperature of from 16° C. to 45° C., a glistening resistance characterized by having no bright field microvacuole and about 10 or less microvacuoles per viewing screen, a Young's modulus of from about 1.0 MPa to about 60.0 MPa, an elongation at break of greater than 90%, and a 25% secant modulus of less than 6.0 MPa. 2. The ophthalmic device material of claim 1 , wherein the device material in the fully hydrated state remains substantially clear or clear, as characterized by having T 23 - T 35 T 23 ≤ 20 ⁢ % , in which T 23 and T 35 are average transmittances between 400 nm to 700 nm of the material at 23° C. and 35° C. respectively when being heated from 23° C. to 35° C. 3. The ophthalmic device material of claim 2 , wherein the device material in the fully hydrated state has a surface light scattering of about 30 CCT or less after 10-years accelerated aging. 4. The ophthalmic device material of claim 2 , wherein in formula (I), B 1 is (CH 2 ) m1 , m1 is 2-5, Y 1 is nothing or O, w1 is 0 or 1, and D 1 is H. 5. The ophthalmic device material of claim 4 , wherein said one or more aryl acrylic monomers are: 2-ethylphenoxy acrylate; 2-ethylphenoxy methacrylate; phenyl acrylate; phenyl methacrylate; benzyl acrylate; benzyl methacrylate; 2-phenylethyl acrylate; 2-phenylethyl methacrylate; 3-phenylpropyl acrylate; 3-phenylpropyl methacrylate; 4-phenylbutyl acrylate; 4-phenylbutyl methacrylate; 4-methylphenyl acrylate; 4-methylphenyl methacrylate; 4-methylbenzyl acrylate; 4-methylbenzyl methacrylate; 2-2-methylphenylethyl acrylate; 2,2-methylphenylethyl methacrylate; 2,3-methylphenylethyl acrylate; 2,3-methylphenylethyl methacrylate; 2,4-methylphenylethyl acrylate; 2,4-methylphenylethyl methacrylate; 2-(4-propylphenyl)ethyl acrylate; 2-(4-propylphenyl)ethyl methacrylate; 2-(4-(1-methylethyl)phenyl)ethyl acrylate; 2-(4-(1-methylethyl)phenyl)ethyl methacrylate; 2-(4-methoxyphenyl)ethyl acrylate; 2-(4-methoxyphenyl)ethyl methacrylate; 2-(4-cyclohexylphenyl)ethyl acrylate; 2-(4-cyclohexylphenyl)ethyl methacrylate; 2-(2-chlorophenyl)ethyl acrylate; 2-(2-chlorophenyl)ethyl methacrylate; 2-(3-chlorophenyl)ethyl acrylate; 2-(3-chlorophenyl)ethyl methacrylate; 2-(4-chlorophenyl)ethyl acrylate; 2-(4-chlorophenyl)ethyl methacrylate; 2-(4-bromophenyl)ethyl acrylate; 2-(4-bromophenyl)ethyl methacrylate; 2-(3-phenylphenyl)ethyl acrylate; 2-(3-phenylphenyl)ethyl methacrylate; 2-(4-phenylphenyl)ethyl acrylate; 2-(4-phenylphenyl)ethyl methacrylate; 2-(4-benzylphenyl)ethyl acrylate; 2-(4-benzylphenyl)ethyl methacrylate; 2-(phenylthio)ethyl acrylate; 2-(phenylthio)ethyl methacrylate; 2-benzyloxyethyl acrylate; 3-benzyloxypropyl acrylate; 2-benzyloxyethyl methacrylate; 3-benzyloxypropyl methacrylate; 2-[2-(benzyloxy)ethoxy]ethyl acrylate; 2-[2-(benzyloxy)ethoxy]ethyl methacrylate; or combinations thereof. 6. The ophthalmic device material of claim 5 , wherein said one or more aryl acrylic monomers are: 2-phenylethyl acrylate; 3-phenylpropyl acrylate; 4-phenylbutyl acrylate; 5-phenylpentyl acrylate; 2-benzyloxyethyl acrylate; 3-benzyloxypropyl acrylate; 2-[2-(benzyloxy)ethoxy]ethyl acrylate; or combinations thereof. 7. The ophthalmic device material of claim 6 , wherein the polymerizable composition comprises from about 1.0% to about 6.0% by weight of the polymerizable crosslinking agent. 8. The ophthalmic device material of claim 7 , wherein the polymerizable crosslinking agent is selected from the group consisting of ethylene glycol dimethacrylate; diethylene glycol dimethacrylate; triethylene glycol dimethacrylate, tetraethylene glycol dimethacrylate, allyl methacrylate; 1,3-propanediol dimethacrylate; 2,3-propanediol dimethacrylate; 1,6-hexanediol dimethacrylate; 1,4-butanediol dimethacrylate; ethylene glycol diacrylate; diethylene glycol diacrylate; triethylene glycol diacrylate, tetraethylene glycol diacrylate, allyl acrylate; 1,3-propanediol diacrylate; 2,3-propanediol diacrylate; 1,6-hexanediol diacrylate; 1,4-butanediol diacrylate; N,N′-hexamethylene bisacrylamide; N,N′-hexamethylene bismethacrylamide; N,N′-dihydroxyethylene bisacrylamide; N,N′-dihydroxyethylene bismethacrylamide; N,N′-methylene bisacrylamide; N,N′-methylene bismethacrylamide; CH 2 ═C(CH 3 )C(═O)O—(CH 2 CH 2 O) p —C(═O)C(CH 3 )═CH 2 where p=1-50; CH 2 ═CHC(═O)O—(CH 2 CH 2 O) p —C(═O)CH═CH 2 where p=1-50; CH 2 ═C(CH 3 )C(═O)O(CH 2 ) t O—C(═O)C(CH 3 )═CH 2 where t=3-20; CH 2 ═CHC(═O)O(CH 2 ) t O—C(═O)CH═CH 2 where t=3-20, and combinations thereof. 9. The ophthalmic device material of claim 5 , wherein the polymerizable composition comprises from about 1.0% to about 6.0% by weight of the polymerizable crosslinking agent. 10. The ophthalmic device material of claim 9 , wherein the polymerizable crosslinking agent is selected from the group consisting of ethylene glycol dimethacrylate; diethylene glycol dimethacrylate; triethylene glycol dimethacrylate, tetraethylene glycol dimethacrylate, allyl methacrylate; 1,3-propanediol dimethacrylate; 2,3-propanediol dimethacrylate; 1,6-hexanediol dimethacrylate; 1,4-butanediol dimethacrylate; ethylene glycol diacrylate; diethylene glycol diacrylate; triethylene glycol diacrylate, tetraethylene glycol diacrylate, allyl acrylate; 1,3-propanediol diacrylate; 2,3-propanediol diacrylate; 1,6-hexanediol diacrylate; 1,4-butanediol diacrylate; N,N′-hexamethylene bisacrylamide; N,N′-hexamethylene bismethacrylamide; N,N′-dihydroxyethylene bisacrylamide; N,N′-dihydroxyethylene bismethacrylamide; N,N′-methylene bisacrylamide; N,N′-methylene bismethacrylamide; CH 2 ═C(CH 3 )C(═O)O—(CH 2 CH 2 O) p —C(

Assignees

Inventors

Classifications

  • A61L27/26Primary

    Mixtures of macromolecular compounds · CPC title

  • G02B1/041Primary

    Lenses · CPC title

  • Hydrogels or hydrocolloids · CPC title

  • for reconstruction of eye parts, e.g. intraocular lens, cornea · CPC title

  • Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials} · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9864102B2 cover?
Acrylate-acrylamide copolymers are disclosed. They are rigid and glassy in dry state at room temperature (from about 23° C. to about 28° C.), but are soft and very deformable and have a high refractive index, a high glistening resistance and a low aging-related surface light scattering in fully hydrated state. They are particularly suitable for making wet-packed intraocular lenses (IOLs) which …
Who is the assignee on this patent?
Novartis Ag
What technology area does this patent fall under?
Primary CPC classification A61L27/26. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jan 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).